Skip to main content
Equibles

ORBIMED ADVISORS LLC

Position in VTGN — Vistagen Therapeutics, Inc.

CIK 1055951 New York, NY
Back to VTGN Full portfolio

Position in VTGN

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$1,744,200
-$275,400 QoQ
Shares Held
3,060,000
0.0% QoQ
Ownership
6.90%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2020
10 quarters on record
Voting authority Sole 46% Shared 0% None 54%

Common Shares in VTGN Over Time

Shares Held

Position Value (USD)

Derivatives in VTGN

reported options exposure · as of Dec 31, 2025
CallValue
$29,832
CallShares
45,200
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ORBIMED ADVISORS LLC holds $3,639,640,835 across 90 Biotechnology names.

# Ticker Company Shares Value (USD) Open
1 EWTX
Edgewise Therapeutics, Inc.
 15,518,492 $630,516,329
2 ELVN
Enliven Therapeutics, Inc.
 6,776,632 $343,914,074
3 MBX
MBX Biosciences, Inc.
 3,428,736 $189,266,227
4 GPCR
Structure Therapeutics Inc.
 2,209,400 $118,578,498
5 SION
Sionna Therapeutics, Inc.
 2,555,877 $112,433,029
6 CRVS
Corvus Pharmaceuticals, Inc.
 7,165,006 $107,045,189
7 AVBP
ArriVent BioPharma, Inc.
 3,027,328 $105,169,374
8 ARGX
Argenx SE
 92,880 $86,171,277

All Filings in VTGN

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $1,744,200 3,060,000
2025-12-31 $2,019,600 3,060,000
2025-12-31 $29,832 45,200
2025-09-30 $10,863,000 3,060,000
2025-09-30 $160,460 45,200
2022-06-30 $11,810,729 13,421,283
2022-03-31 $16,007,510 12,909,283
2021-12-31 $25,173,101 12,909,283
2021-09-30 $35,371,435 12,909,283
2021-06-30 $45,573,796 14,467,872
2021-03-31 $18,326,519 8,604,000
2020-12-31 $14,549,999 7,500,000